Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging

The objective of our study is to assess change in QTc interval with Regadenoson administration during myocardial perfusion imaging (MPI). We conducted a retrospective, observational analysis of 1497 consecutive patients who underwent pharmacological radionuclide MPI. On multivariate logistic regress...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafiq, Arsalan, Chughtai, Tausif, Ashraf, Umair, Patel, Yash, Raiszadeh, Farbod, Sklyar, Eduard, Afshar, Maryam, Bella, Jonathan N., Kamalakkannan, Gayathri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474107/
https://www.ncbi.nlm.nih.gov/pubmed/32861387
http://dx.doi.org/10.1016/j.ihj.2020.06.015
Descripción
Sumario:The objective of our study is to assess change in QTc interval with Regadenoson administration during myocardial perfusion imaging (MPI). We conducted a retrospective, observational analysis of 1497 consecutive patients who underwent pharmacological radionuclide MPI. On multivariate logistic regression analyses, there was no statistical significance of QTc prolongation when adjusted for ischemia/fixed perfusion defect on MPI and QT prolonging medications being taken prior to stress testing. However, a positive stress ECG after Regadenoson injection had a statistical significance (p value 0.0004). Regadenoson is a safe drug for use in MPI with little, if any, side effects of major clinical significance.

Ejemplares similares